Consequences of Inaccessible CTMS Data
Do you have meaningful control of your data? You might legally own the information, but do you have access, control, and portability?
From our whitepaper, “How the Right CTMS Enables Meaningful Data Ownership,” this excerpt examines the cost of inaccessible data.
Ownership in name only
Clinical trial data has emerged as an essential contributor to the healthcare industry, driving innovation in both technology and treatment. Effective trial management not only generates quality data, but can impact the ability of that data to be put to use—driving stronger insights, improved processes, and more effective oversight, all while powering better outcomes.
But data flexibility and portability are key to this effort. When spread across multiple different systems, data cannot easily be accessed or packaged. Disparate and/or discordant systems make it hard for data to be utilized in an all-inclusive way to drive quality decision-making.
Sponsors may feel that outsourcing has dampened their access to accurate, up-to-date details about study progress and performance. CROs may have multiple data sources from multiple sponsors that they are trying to use as inputs for their study management responsibilities. In addition, CROs may want systems designed for data liberation—where they can share reports, exports, charts, and even allow API access to sponsors.
In all cases, having reliable access to your data with the ability to easily collect and disseminate study information is key.
Consequences of inaccessible data
Within the clinical trial ecosystem, it is the sponsor who remains responsible for the data quality and informational integrity of the trial. When data is managed using completely different systems across study teams, the following problems might arise:
Access and usability issues – You can’t use what you can’t see.
Data loss during migration and/or conversion – Valuable information may be lost in translation.
Lost opportunities for leveraging raw data – Piecemeal data sets across multiple systems means forfeiting the chance to see the big picture.
Accountability and legal obligation – Privacy and patient rights cannot be meaningfully addressed without hands-on data ownership.
Working with a CRO (or any other type of partner) shouldn’t—and doesn’t—require giving up access and control over your findings. The right solution enables retaining meaningful control over your data, regardless of whether you manage trials in-house or through a CRO.
Sponsors should choose the systems their data utilizes, and make that choice based on the best fit for their ultimate data purposes. And to reduce the need for multiple platforms and system formats, opting for one comprehensive, full-featured system allows sponsors to capture data in one organized place.
With the right Clinical Trial Management System (CTMS), sponsors can exponentially simplify operations and oversight, especially when managing multiple studies at a time.
Unpack the crucial CTMS characteristics that can help you optimize your trial management, enabling more effective ownership: better control, portability, and usage of your data.
Read the full whitepaper here.